p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma

  • Authors:
    • Joon Kyoo Lee
    • Kyung‑Hwa Lee
    • Sun‑Ae Kim
    • Sun Seog Kweon
    • Sang‑Hee Cho
    • Hyun‑Jeong Shim
    • Woo‑Kyun Bae
    • Ik‑Joo Chung
    • Woong‑Ki Chung
    • Tae Mi Yoon
    • Sang Chul Lim
    • Dong Hoon Lee
  • View Affiliations

  • Published online on: March 1, 2018     https://doi.org/10.3892/ol.2018.8138
  • Pages: 6571-6577
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study was conducted to investigate the prognostic significance of p16 (also known as cyclin-dependent kinase inhibitor 2A) in the treatment of induction chemoradiotherapy for advanced hypopharyngeal squamous cell carcinoma (HPSCC). Patients who were treated with at least two cycles of induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced HPSCC were reviewed in the study. The staining results were analyzed to examine the association between the chemotherapy response and the survival outcome. A total of 45 patients were enrolled for the present study; the majority had received induction chemotherapy with docetaxel, cisplatin, and 5‑FU. Following induction chemotherapy, 17 patients (37.8%) exhibited a complete response and 28 patients (62.2%) exhibited a partial response. There were 11 patients (24.4%) with p16‑positive immunohistochemical stains and 30 patients (66.7%) with p53‑positive immunohistochemical stains. There was no significant difference in chemotherapy response, overall survival, or progression‑free survival time between groups with p16‑positive and p16‑negative stains. Low p53 expression and chemotherapy response were not associated with each other. High p16 expression did not correlate with low p53 expression. In this study, p16 was not determined to predict the chemotherapy response for HPSCC. High p16 expression did not correlate with survival incidence for patients with HPSCC.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee JK, Lee KH, Kim SA, Kweon SS, Cho SH, Shim HJ, Bae WK, Chung IJ, Chung WK, Yoon TM, Yoon TM, et al: p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma. Oncol Lett 15: 6571-6577, 2018
APA
Lee, J.K., Lee, K., Kim, S., Kweon, S.S., Cho, S., Shim, H. ... Lee, D.H. (2018). p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma. Oncology Letters, 15, 6571-6577. https://doi.org/10.3892/ol.2018.8138
MLA
Lee, J. K., Lee, K., Kim, S., Kweon, S. S., Cho, S., Shim, H., Bae, W., Chung, I., Chung, W., Yoon, T. M., Lim, S. C., Lee, D. H."p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma". Oncology Letters 15.5 (2018): 6571-6577.
Chicago
Lee, J. K., Lee, K., Kim, S., Kweon, S. S., Cho, S., Shim, H., Bae, W., Chung, I., Chung, W., Yoon, T. M., Lim, S. C., Lee, D. H."p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma". Oncology Letters 15, no. 5 (2018): 6571-6577. https://doi.org/10.3892/ol.2018.8138